Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and
Marek Widera1, Alexander Wilhelm1,2, Tuna Toptan1
1Institute for Medical Virology, University Hospital Frankfurt am Main, Goethe University, Frankfurt am Main, Germany.
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. The common methods to monitor and quantitate SARS-CoV-2 infectivity in cell culture are so far time-consuming and labor-intensive. Using the Sleeping Beauty transposase system, we generated a robust and versatile cellular infection model that allows SARS-CoV-2 infection experiments compatible for high-throughput and live cell imaging. The model is based on lung derived A549 cells, which show a profound interferon response and convenient cell culture characteristics. ACE2 and TMPRSS2 were introduced for constitutive expression (A549-AT). Subclones with varying levels of ACE2/TMPRSS2 were screened for optimal SARS-CoV-2 susceptibility. Furthermore, extensive evaluation demonstrated that SARS-CoV-2 infected A549-AT cells were distinguishable from mock-infected cells and already showed approximately 12 h post infection a clear signal to noise ratio in terms of cell roughness, fluorescence and a profound visible cytopathic effect. Moreover, due to the high transfection efficiency and proliferation capacity, Sleeping Beauty transposase-based overexpression cell lines with a second inducible fluorescence reporter cassette (eGFP) can be generated in a very short time, enabling the investigation of host and restriction factors in a doxycycline-inducible manner. Thus, the novel model cell line allows rapid and sensitive monitoring of SARS-CoV-2 infection and the screening for host factors essential for viral replication.
Insights
Researchers developed a new cell model for studying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity. This high-throughput model enables rapid and sensitive monitoring of SARS-CoV-2, aiding in the discovery of host factors essential for viral replication.
Area of Science:
- Virology
- Cell Biology
- Infectious Diseases
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a global health concern.
- Current methods for monitoring SARS-CoV-2 infectivity in cell culture are time-consuming and labor-intensive.
Purpose of the Study:
- To develop a robust and versatile cellular infection model for high-throughput and live cell imaging of SARS-CoV-2.
- To enable rapid and sensitive monitoring of SARS-CoV-2 infection and screening for host factors.
Main Methods:
- Utilized the Sleeping Beauty transposase system to create a SARS-CoV-2 infection model using A549 lung cells.
- Introduced ACE2 and TMPRSS2 for constitutive expression (A549-AT) and screened subclones for optimal SARS-CoV-2 susceptibility.
- Incorporated an inducible fluorescence reporter cassette (eGFP) for doxycycline-inducible expression of host/restriction factors.
Main Results:
- SARS-CoV-2 infected A549-AT cells showed clear, distinguishable signals (cell roughness, fluorescence, cytopathic effect) approximately 12 hours post-infection.
- The model demonstrated a good signal-to-noise ratio, facilitating infection monitoring.
- Sleeping Beauty transposase enabled rapid generation of cell lines with high transfection efficiency and proliferation capacity.
Conclusions:
- The novel A549-AT cell line serves as an efficient model for SARS-CoV-2 infection studies.
- This model supports high-throughput screening for antiviral drugs and investigation of host-pathogen interactions.
- Enables rapid and sensitive monitoring of SARS-CoV-2 and identification of essential host factors for viral replication.
More Related Videos
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
